Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies

To date, the RV144 HIV vaccine trial has been the only study to show that immunization can confer protection from HIV infection. While encouraging, the modest 31.2% (P = 0.04) efficacy achieved in this study left significant room for improvement, and created an incentive to optimize the AIDSVAX B/E...

Descripción completa

Detalles Bibliográficos
Autores principales: Doran, Rachel C., Tatsuno, Gwen P., O’Rourke, Sara M., Yu, Bin, Alexander, David L., Mesa, Kathryn A., Berman, Phillip W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916523/
https://www.ncbi.nlm.nih.gov/pubmed/29689099
http://dx.doi.org/10.1371/journal.pone.0196370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916523/
https://www.ncbi.nlm.nih.gov/pubmed/29689099
http://dx.doi.org/10.1371/journal.pone.0196370

Ejemplares similares